Inflammation is the body’s defence system, a way of responding to injury or infection. One key molecule involved in the ...
Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, ...
R Dr Eneas de Carvalho Aguiar 470, Instituto de Medicina Tropical (IMT), Cerqueira Cesar, São Paulo, SP, 05403 903, Brazil Tel.: +55 11 3061 7457 Fax: +55 11 3081 7190 mahong@usp.br Establishing that ...
Context: Current pharmacologic treatments for Alzheimer's disease (AD) do not prevent long-term clinical deterioration. Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
Megan E.B. Clowse, MD: TNF inhibitors are a class of medications that have now been on the market for 20 years and have really revolutionized the management of inflammatory arthritis. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback